Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

NeuroCure

Financiado

Novel nanosized GDNF mimetics for the treatment of Parkinson’s disease: focus on...

Novel nanosized GDNF mimetics for the treatment of Parkinson’s disease: focus onto non-dopaminergic features PD is the most common age-related neurodegenerative disorder that is characterized by four pathognomonic hallmarks: 1) motor and non-motor deficits; 2) progressive loss of nigrostriatal dopamine neurons; 3) pathological aggregates... ver más

07/01/2026

HELSINGIN YLIOPIST...

200K€

Presupuesto del proyecto: 200K€

Líder del proyecto

HELSINGIN YLIOPISTO No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-05-05

HORIZON-MSCA-2022-PF-01-01: MSCA Postdoctoral Fellowships 2022 ExpectedOutcome:

I+D

Cerrada hace 2 años

0% 100% 100%

1 Participantes

HELSINGIN YLIOPISTO

199.69K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SAF2012-33816 CARACTERIZACION DE LOS MECANISMOS INTRINSECOS IMPLICADOS EN... 187K€ Cerrado

SAF2009-06977 MECANISMOS DE MANTENIMIENTO DE NEURONAS ADULTAS CETECOLAMINE... 178K€ Cerrado

ReTreatPD Revolutionary therapeutic treatment for stopping progression... 4M€ Cerrado

PID2019-108792GB-I00 DISECCION DE MECANISMOS PATOGENICOS EN LA ENFERMEDAD DE PARK... 192K€ Cerrado

PID2019-105995RB-I00 ENVEJECIMIENTO Y REGULACION DE LA EXPRESION DE GDNF EN EL CU... 168K€ Cerrado

PID2019-111045RB-I00 STOPPING NIGRO-STRIATAL DEGENERATION IN PARKINSON DISEASE: F... 298K€ Cerrado

Duración del proyecto: 32 meses Fecha Inicio: 2023-05-05
Fecha Fin: 2026-01-07

Líder del proyecto

HELSINGIN YLIOPISTO No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 200K€

Descripción del proyecto PD is the most common age-related neurodegenerative disorder that is characterized by four pathognomonic hallmarks: 1) motor and non-motor deficits; 2) progressive loss of nigrostriatal dopamine neurons; 3) pathological aggregates of the α-synuclein (α-syn) protein; 4) neuroinflammation and oxidative stress. There is no single treatment currently available (or being tested) that can affect mechanisms of the disease, promote regeneration or at least protection of dopamine (and other affected neurons), and alleviate both motor and non-motor symptoms. Importantly, non-motor symptoms severely alter the quality of life of the patients since they are even more debilitating than the motor ones and do not respond to dopaminergic-based therapies. One of the therapeutically potent approaches to combat PD is neurotrophic factors (NTFs)-based therapies, particularly the glial cell line-derived neurotrophic factor (GDNF). GDNF demonstrated encouraging survival-promoting effects on dopamine neurons in diverse PD animal models and held a great hope as a neuroprotective treatment. Also, GDNF has positive impact in a number of other neurons such as sensory, enteric, olfactory, etc., which degeneration or dysfunction is associated with the appearance of non-motor symptoms. Despite of the promising results, GDNF due to poor tissue distribution and inability to pass through the blood brain barrier should be delivered to the brain through a risky surgery. To overcome the delivery problems and finally utilize the potential of GDNF in PD management proposed project combines neurobiology, translational biology, and experimental pharmacology to develop nanosized GDNF mimetic-based drug candidate that will 1) positively impact the disease progression through mitigation of the pathogenesis associated with α-syn aggregations and neuroinflammation, 2) support the survival of human dopamine neurons in vitro and 3) alleviate motor and non-motor symptoms of PD in vivo.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores